TECX: Tectonic Therapeutic Company Value to Net Income

Corporate emblem and logo of Tectonic Therapeutic (TECX)

Tectonic Therapeutic, Inc. (TECX) is led by top scientists developing high-precision platforms to combat various pathologies. The business model is independent of economic cycles or seasonality, demonstrating resilience to external shocks. Operational activities are based on engaging third-party laboratories while maintaining full control over intellectual property. This chart of current share prices reflects a PE ratio of -4.70.

TECX Tectonic Therapeutic Inc.: Price to Earnings Ratio in the range 06/22/2024 - 11/17/2026

Comprehensive metric breakdowns and analytics for Tectonic Therapeutic Inc. (TECX)

- price and consensus price forecast:
- market capitalization information:
Comprehensive company analysis:Tectonic - TECX
Flagship merchandise of Tectonic Therapeutic

For Tectonic Therapeutic, Inc. (TECX), the efficiency of AI integration into molecular design directly impacts future capitalization. The P/E ratio measures the market value of a single share relative to net income, determining the investment payback period. By analyzing the company's historical P/E chart, one can identify valuation deviations from fundamental indicators during clinical trial periods. Comparing this metric with the industry average allows for balancing the risk of overpayment against growth potential.

Competing companies

HLN: Company Value to Net Income|Price to Earnings Ratio KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Limited MENS|Ligand (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|Perrigo - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Technologies - Company Value to Net Income|GLPG (Galapagos N.V.) - P/E Multiple|Market Cap to Earnings anipharmaceuticals.com ANIP|Price to Earnings Ratio MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Company Value to Net Income|Price to Earnings Ratio Pacira BioSciences, Inc. PCRX|P/E Multiple ARS Corp SPRY|Theravance Biopharma - P/E Multiple|Market Cap to Net Income Ratio Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Price to Earnings Ratio|Price to Earnings Multiple TNXP|Price to Earnings Ratio China SXT Pharmaceuticals, Inc.|EPRX: Company Value to Net Income|P/E Multiple BHST|EXOZ - Market Cap to Earnings|P/E Multiple ORMP (oramed.com)|P/E Multiple enterabio.com ENTX|HYFT - Price to Earnings Ratio|Business Payback Period ABVC BioPharma, Inc ABVC|CPIX: P/E Multiple|Quantum BioPharma Ltd - Company Value to Net Income|Price to Earnings Ratio FGEN|Telomir Pharmaceuticals, Inc. - Market Cap to Net Income|P/E Multiple RANI|SNYR (Synergy CHC) - Company Value to Net Income|Price to Earnings Ratio Rallybio RLYB|Lexaria Bioscience (LEXX) - Market Cap to Earnings|PULM - Price to Earnings Ratio|Business Payback Period Pheton Holdings PTHL|APM (Aptorum) - Price to Earnings Ratio|Lyra Therapeutics, Inc. (LYRA) - P/E Multiple|IBO (impactbiomedinc.com) - P/E Multiple|TNFA (TNF Pharmaceuticals) - Market Price to Net Income Ratio|Price to Earnings Ratio cbdmd.com (YCBD)|Business Payback Period PainReform Ltd|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|Pieris Pharmaceuticals - Market Price to Net Income Ratio|PROC (Procaps Group) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding Group Limited|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)